title: A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
abstract: OBJECTIVE
  This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma.
  
  
  METHODS
  This study included 10 patients with histologically confirmed adenocarcinoma of the esophagus or esophagogastric junction between April 2005 and August 2011. S-1 was administered orally at a dose of 80 mg/m²/day from day 1 to 14 and irinotecan was given intravenously on day 1 and 8 at a dose of 80 mg/m².
  
  
  RESULTS
  A total of 65 cycles were administered and the response rate was 62.5%. The 50% progression-free survival period and the 50% overall survival period for all of the patients was 8.4 months and 19.1 months, respectively and 5.9 months and 16.3 months for the 8 patients with unresectable or recurrent tumors, respectively. The 2 patients that received adjuvant chemotherapy demonstrated a prophylactic effect for the post-operative recurrence. On the other hand, this therapy showed no severe non-hematological toxicity and only 20% experienced grade 3 neutropenia. As a result, the treatment regimen could generally be performed in an outpatient basis.
  
  
  CONCLUSIONS
  The combination chemotherapy using S-1 and irinotecan showed tolerable clinical efficacy in terms of the response rate, survival and toxicity for esophageal adenocarcinoma.
authors.affiliation: Department of Esophago-Gastric Surgery, Tokyo Medical and Dental University, Tokyo, Japan. yasu.nakajima.srg1@tmd.ac.jp
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Naoto
authors.initials: N
authors.lastname: Fujiwara
authors.forename: Tairo
authors.initials: T
authors.lastname: Ryotokuji
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Ohta
authors.forename: Takuya
authors.initials: T
authors.lastname: Okada
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Miyawaki
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hoshino
authors.forename: Swangsri
authors.initials: S
authors.lastname: Jirawat
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tokairin
authors.forename: Kenro
authors.initials: K
authors.lastname: Kawada
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Nishikage
authors.forename: Kagami
authors.initials: K
authors.lastname: Nagai
authors.forename: Tatsuyuki
authors.initials: T
authors.lastname: Kawano
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000473:pathology*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D010865:Pilot Projects; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin